Bortezomib Re-treatment in Patients with Multiple Myeloma (MM). A Real World Medical Practice Experience from a Swedish National Registry

Value Health. 2014 Nov;17(7):A617. doi: 10.1016/j.jval.2014.08.2181. Epub 2014 Oct 26.

Authors

P Thilakarathne¹, J Diels², S van Sanden³, J Liwing⁴, O Chirita⁵, M Van Agthoven⁶, H Nahi⁷

Affiliations

¹ Janssen Pharmaceutica N. V., Beerse, Belgium.
² Janssen Research & Development, Beerse, Belgium.
³ EMEA HEMAR Analytics, Janssen EMEA, Beerse, Belgium.
⁴ Janssen-Cilag AB, Sollentuna, Sweden.
⁵ Janssen, High Wycombe, UK.
⁶ Janssen-Cilag BV, Tilburg, The Netherlands.
⁷ Karolinska University Hospital, Solna, Sweden.

PMID: 27202162
DOI: 10.1016/j.jval.2014.08.2181

No abstract available